The company's lead product candidate is Cytisinicline, a plant-based alkaloid, which is believed to aid in smoking cessation.
On July 20, the company announced the publication of the first paper on the use of Bionano's Saphyr genome imaging instrument to investigate the performance of Bionano data in comparison to the cytogenetic standard of care in constitutional or inherited genetic disorders.Īccording to the authors of the paper, there was a 100% concordance between optical mapping results from the Saphyr genome imaging instrument and gold standard cytogenetic methods consisting of a combination of karyotyping, FISH, and/or chromosomal microarray in a cohort of patients with a variety of constitutional or inherited genetic disorders.Īchieve Life is over 10% at $0.60 in pre-market trading today on no news. TRUFORMA, the company's inaugural point-of-care diagnostic device, introduces highly sensitive, species-specific assays for the diagnosis of thyroid disease in dogs and cats and adrenal disease in dogs.īionano is up more than 14% at $0.94 in pre-market trading, adding to yesterday's gain of over 20%.
(ZOM), a veterinary health company, are up over 22% at $0.19 in pre-market trading Wednesday, following a successful implementation of its first completely remote installations of TRUFORMA. JERUSALEM (dpa-AFX) - What's moving these stocks in the pre-market hours today?
0 kommentar(er)
